Photo Gallery

Login

Search

News & Updation

  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • WJPPS Impact Factor
  • Its our Pleasure to Inform you that WJPPS Impact Factor has been increased from  7.454 to 7.632  due to high quality Publication at International Level

  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • WJPPS OCTOBER ISSUE PUBLISHED
  • OCTOBER 2020 Issue has been successfully launched on 1 October 2020.

Abstract

EVALUATING RISK OF HEART FAILURE WITH ERYTHROPOIETIN IN CHRONIC ANEMIA

*Dr. S. P. Srinivas Nayak, Syeda Maimoona Maqsood, Azgari Begum, Sania Mehveen, Lubna Muzaffar Hussain

ABSTRACT

Erythropoietin (EPO) is the primary regulatory hormone of erythropoiesis. Hypoxia induces an increase in EPO hormone production in the kidney which promotes the viability, proliferation, and terminal differentiation of erythroid precursors, and causing an increase in red blood cell mass. Any abnormality that reduces the renal secretion of or bone marrow response to erythropoietin may result in anemia. The approval of recombinant human erythropoietin (epoetinalfa) by the US FDA in 1989, epoetinalfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia. Studies suggest that in patients with high serum erythropoietin is associated with risk of recurrent heart failure (HF) and mortality. Thromboembolic complications can be increased in patients receiving erythropoietin. the use of erythropoiesis-stimulating agents though reduces the need for transfusions it is associated with increased complications, including higher mortality and increased risk of thromboembolic and cardiovascular events leading to congestive heart failure.

Keywords: Erythropoietin, Hypoxia, Erythropoietin-Deficient Anemia and Heart Failure.


[Full Text Article]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More